Skip to main content


Media Coverage

FTC's New Rule Zeroes In On More Pharma Patent Deals

13 August 2012
Litigation & Dispute Resolution partner Chris Kelly (Palo Alto) is quoted on the FTC’s new plans to broaden the types of exclusive pharmaceutical patent rights licenses that require antitrust approval.
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.